company background image
AMPH logo

Amphastar Pharmaceuticals Informe acción NasdaqGS:AMPH

Último precio

US$41.11

Capitalización de mercado

US$2.0b

7D

2.7%

1Y

14.9%

Actualizada

28 Apr, 2024

Datos

Finanzas de la empresa +

Amphastar Pharmaceuticals, Inc.

Informe acción NasdaqGS:AMPH

Capitalización de mercado: US$2.0b

Resumen de acción AMPH

Amphastar Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica, comercializa y vende productos genéricos y patentados inyectables, inhalables e intranasales en Estados Unidos, China y Francia.

AMPH fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance6/6
Financial Health3/6
Dividends0/6

Competidores de Amphastar Pharmaceuticals, Inc.

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Amphastar Pharmaceuticals
Historical stock prices
Current Share PriceUS$41.11
52 Week HighUS$67.66
52 Week LowUS$35.69
Beta0.84
1 Month Change-6.38%
3 Month Change-25.78%
1 Year Change14.93%
3 Year Change136.26%
5 Year Change83.94%
Change since IPO310.69%

Noticias y actualizaciones recientes

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Recent updates

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

Mar 04

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today

Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E

Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet

Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

Sep 18
Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth

An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

Sep 03
An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Aug 17
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

Jun 02
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

May 11
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Mar 02
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price

Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Feb 07
Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?

Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Jan 24
Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?

Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Nov 02
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors

Amphastar: A Pharmaceutical Growth Stock

Oct 06

Amphastar wins FDA approval for Epinephrine pre-filled syringes

Aug 16

Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond

Aug 08

Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Jul 24
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?

Amphastar generic vasopressin for increasing blood pressure gets FDA approval

Jul 19

We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Jun 10
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease

Amphastar Pharmaceuticals: Stock With An Attractive 6 To 1 Risk-Reward Ratio

May 13

I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

Apr 23
I Ran A Stock Scan For Earnings Growth And Amphastar Pharmaceuticals (NASDAQ:AMPH) Passed With Ease

These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Feb 13
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely

Amphastar Pharma: A Well-Run, Diversified Mid Cap

Jan 26

Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

Jan 08
Should You Be Adding Amphastar Pharmaceuticals (NASDAQ:AMPH) To Your Watchlist Today?

Rentabilidad de los accionistas

AMPHUS PharmaceuticalsMercado US
7D2.7%0.7%2.9%
1Y14.9%10.8%22.2%

Rentabilidad vs. Industria: AMPH superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 10.6% el año pasado.

Rentabilidad vs. Mercado: AMPH obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is AMPH's price volatile compared to industry and market?
AMPH volatility
AMPH Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Precio estable de las acciones: El precio de las acciones de AMPH ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de AMPH (6%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
19961,761Jack Zhangwww.amphastar.com

Amphastar Pharmaceuticals, Inc. es una empresa biofarmacéutica que desarrolla, fabrica, comercializa y vende productos genéricos y patentados inyectables, inhalables e intranasales en Estados Unidos, China y Francia. Ofrece BAQSIMI, un aerosol nasal para el tratamiento de la hipoglucemia grave; Primatene Mist, un producto de inhalación de epinefrina de venta libre para el alivio temporal de los síntomas leves del asma intermitente; Enoxaparin, para prevenir y tratar la trombosis venosa profunda; REXTOVY y Naloxone para la sobredosis de opiáceos; Glucagon para kit de emergencia inyectable; y Cortrosyn, para su uso como agente de diagnóstico en el cribado de pacientes con insuficiencia corticosuprarrenal. La empresa suministra Amphadase, una inyección para absorber y dispersar otros fármacos inyectados; Epinefrina inyectable para reacciones alérgicas; Lidocaína en gel, un producto anestésico para procedimientos urológicos; Lidocaína en solución tópica para diversos procedimientos; Fitonadiona inyectable, una inyección de vitamina K1 para recién nacidos; productos de jeringuillas de emergencia; Morfina inyectable para su uso con bombas de analgesia controlada por el paciente; y Lorazepam inyectable para cirugía y procedimientos médicos.

Resumen de fundamentos de Amphastar Pharmaceuticals, Inc.

¿Cómo se comparan los beneficios e ingresos de Amphastar Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de AMPH
Capitalización bursátilUS$2.01b
Beneficios(TTM)US$137.55m
Ingresos (TTM)US$644.40m

14.6x

Ratio precio-beneficio (PE)

3.1x

Ratio precio-ventas (PS)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de AMPH
IngresosUS$644.40m
Coste de los ingresosUS$290.57m
Beneficio brutoUS$353.82m
Otros gastosUS$216.28m
BeneficiosUS$137.55m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)2.81
Margen bruto54.91%
Margen de beneficio neto21.34%
Ratio deuda/patrimonio92.2%

¿Cómo se ha desempeñado AMPH a largo plazo?

Ver rendimiento histórico y comparativa